Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Fatigue 6Neoplasms 5Breast Neoplasms 5Anxiety Disorders 3Psychological Well-Being 2Pain 2Lung Neoplasms 2Gastrointestinal Neoplasms 2Esophageal Neoplasms 2Depression 2Caregiver Burden 2Uterine Neoplasms 1Tuberous Sclerosis 1Substance-Related Disorders 1Sleep Wake Disorders 1Sleep Initiation and Maintenance Disorders 1Prostatic Neoplasms 1Pancreatic Neoplasms 1Pain, Postoperative 1Ovarian Neoplasms 1Neoplasm Regression, Spontaneous 1Multiple Myeloma 1Malignant Hepatobiliary Neoplasm 1Lymphoma 1Leukemia 1Hematopoietic Cell Transplantation Recipient 1Glioblastoma 1Colorectal Neoplasms 1Cognitive Dysfunction 1Chronic Pain 1

Interventions

Ultrasonic Waves 1Focus Groups 1Ethanol 1Educational Status 1Cognitive Behavioral Therapy 1Behavior Therapy 1Acceptance and Commitment Therapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase NA × Substance-Related Disorders × Acceptance and Commitment Therapy × Clear all
NCT05643027 2026-05-14

ACTION

Dana-Farber Cancer Institute

Phase NA Completed
40 enrolled

Neoplasms, Substance-Related Disorders

Data powered by HemOnc (CC BY 4.0) Colophon âš¡